Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
August 08, 2020 at 13:13 PM EDT
BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture, and market AstraZeneca's COVID-19 vaccine in China. Biogen announced a $2 billion deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.
